All coverage
Angela Merkel rejects US move to waive patents on vaccines
By Guy Chazan, Hannah Kuchler & Jim Brunsden
All you need to know about the battle over COVID jab IP rights
By Virginia Pietromarchi
TRIPS waiver: there's more to the story than vaccine patents
By Hyo Yoon Kang, Siva Thambisetty & Jocelyn Bosse
Pharmaceutical firms’ shares tumble after US plans patent waiver on Covid vaccines
By Julia Kollewe
Biden Backs Waiving International Patent Protections For COVID-19 Vaccines
By Ashish Valentine & Emma Bowman
Germany rejects U.S. proposal to waive patents on COVID-19 vaccines
By Madeline Chambers, Andreas Rinke & Douglas Busvine
Explained: Intellectual property waiver for Covid-19 vaccines
By Prabha Raghavan & Aanchal Magazine
U.S. backs waiving patent protections for Covid vaccines, citing global health crisis
By Thomas Franck, Kevin Breuninger & Amanda Macias
Waiver of patent rights on Covid-19 vaccines, in near term, may be more symbolic than substantive
By Damian Garde, Matthew Herper & Helen Branswell
Covid: The vaccine patent row explained
By Dharshini David
U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents
By Jeff Mason, David Lawder & Andrea Shalal-Esa